Alpha 2.0
Login Register
» Authors » Koichi Takayama

Koichi Takayama

Explore the profile of Koichi Takayama including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 306
Citations 3989
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
General Medicine
Top 10 Co-Authors
Tadaaki Yamada
Yoichi Nakanishi
Junji Uchino
Yusuke Chihara
Masahiro Iwasaku
Taishi Harada
Takayuki Takeda
Yoshiko Kaneko
Kenji Morimoto
Shinsuke Shiotsu
Published In
Lung Cancer
Transl Lung Cancer Res
Cancer Sci
Oncologist
J Thorac Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial
Shukuya T, Asao T, Goto Y, Mimori T, Takayama K, Kaira K, et al.
Lancet Oncol . 2025 Mar; 26(3):331-342. PMID: 40049197
Background: Despite the poor prognosis of advanced or recurrent thymic carcinoma, the rarity of thymic carcinoma has delayed the development and introduction of novel pharmacotherapy options. Carboplatin plus paclitaxel remains...
2.
Factors Contributing to Blood Glucose Elevation Associated With Olanzapine Used as an Antiemetic During Cancer Chemotherapy
Kanbayashi Y, Ishikawa T, Taguchi T, Takayama K
In Vivo . 2025 Feb; 39(2):902-908. PMID: 40010992
Background/aim: This retrospective study aimed to identify factors contributing to blood glucose elevation associated with olanzapine use and to develop new strategies involving olanzapine aimed at enhancing quality of life...
3.
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study
Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, et al.
Lung Cancer . 2025 Feb; 201:108447. PMID: 39970730
Objectives: In patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations, a chemoimmunotherapy regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) has shown promising outcomes...
4.
Survival benefit and potential markers of chemotherapy for elderly and poor performance status patients with advanced non-small cell lung cancer: Results from the Japanese Joint Committee of lung cancer registry database
Ikeda S, Ogura T, Miyaoka E, Sekine I, Shukuya T, Takayama K, et al.
Lung Cancer . 2025 Feb; 200:108102. PMID: 39924255
Introduction: Data on chemotherapy for elderly, poor performance status (PS) non-small cell lung cancer (NSCLC) are clinically important but insufficient due to their exclusion from most interventional studies. This study...
5.
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients
Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, et al.
Lung Cancer . 2025 Jan; 200:108104. PMID: 39889466
Background: Clinical trial eligible patients with advanced non-small cell lung cancer (aNSCLC) and low programmed cell death ligand 1 (PD-L1) expression achieve greater benefit from immune checkpoint inhibitor (ICI) combination...
6.
Plain language summary of a clinical study: anamorelin for treatment of Japanese people with non-small cell lung cancer and cachexia
Takayama K
Future Oncol . 2025 Jan; 20(24):1713-1722. PMID: 39882688
No abstract available.
7.
Plain language summary of a clinical study: anamorelin for treatment of Japanese people with gastrointestinal cancer and cachexia
Takayama K, Furuse J, Muro K
Future Oncol . 2025 Jan; 20(25):1779-1788. PMID: 39882672
No abstract available.
8.
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort Study
Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, et al.
Clin Lung Cancer . 2025 Jan; PMID: 39864962
Background: Although chemoimmunotherapy is recommended for advanced nonsquamous non-small cell lung cancer (NSCLC) with low programmed cell death ligand 1 (PD-L1) expression, no head-to-head comparisons of immune checkpoint inhibitors (ICIs)...
9.
Cynaropicrin Increases [Ca] and Ciliary Beat Frequency in Human Airway Epithelial Cells by Inhibiting SERCA
Todo N, Hosogi S, Nakamura S, Noriyama K, Tamiya N, Toda Y, et al.
Biol Pharm Bull . 2024 Dec; 47(12):2119-2126. PMID: 39710380
Mucociliary clearance (MCC) is a host defense mechanism of the respiratory system. Beating cilia plays a crucial role in the MCC process and ciliary beat frequency (CBF) is activated by...
10.
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy
Kawachi H, Yamada T, Tamiya M, Negi Y, Kijima T, Goto Y, et al.
Oncoimmunology . 2024 Dec; 14(1):2442116. PMID: 39681395
This retrospective, multicenter cohort study aimed to determine whether cancer cachexia serves as a biomarker for determining the most effective treatment for patients having non-small-cell lung cancer (NSCLC) with high...